Oncology Central

NICE approve Alecensa as first-line treatment for ALK-positive NSCLC

The UK’s National Institute for Health and Care Excellence (NICE) have issued approval for Alecensa® (alectinib) as the first-line treatment for untreated adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).

Alecensa was previously available via the Early Access to Medicines Schemes; however, with this NICE approval all patients with ALK-positive NSCLC will now be able to access the drug via NHS routine funding. The drug, which was developed by Roche (Basel, Switzerland), has demonstrated improved outcomes compared with the standard of care, for example, a reduced risk of brain metastases – a common problem in these patients.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.